Digital Productivity
Organizations
Conferences
Info & Opinion
May 12, 2008
Blurring the line between sponsor and CRO, the firm wants promising compounds to take into early-stage development.
The UK-based recruiting and trial-management firm uses untraditional recruiting methods and has a massive backlog of clients.
Ohio-based Prologue is doing well, thanks to expertise and surging market conditions. The company is choosy about hiring.
The large CRO recently moved its headquarters and went from public to private.
The ramifications of a deal that may never come to pass.
Research on the spine is where cardiac research was 10 years ago, declares Marcy Rogers. And that’s why she’s working hard to establish a presence in what she considers a soon-to-boom field. Enter, then, San Diego-based SpineMark CRO Management, the industry’s sole spine-only contract research organization (CRO), launched in 2005… more...
As contract research organizations (CRO) struggle to launch not just more trials but more complex studies, tension is built-in. A sponsor may ask that the CRO use a particular electronic data capture (EDC) supplier. But the sheer profusion of EDC vendors obligates some CROs to learn more than one system.… more...
Some industries simply move jobs to India. Simple. Done. In pharma, the situation is more complex. John Balian, senior VP of global pharmacovigilance and epidemiology at Bristol-Myers Squibb (BMS) told the huge 2008 “Partnerships With CROs” conference in Las Vegas this week that his company has also had a more… more...
What if patients were easy to find? What if you knew all their concommitant meds and it didn’t really matter? What if you could generate a quick-and-dirty answer to the number of people taking medicine X and having adverse event Y? Those were the extremely juicy questions at the heart… more...
Sponsors certainly have plenty of risk these days. For those that would prefer not to finance a compound through the early phase of its life cycle, there’s a contract research organization (CRO) willing to share the uncertainty and, should it materialize, the reward. Wilmington, N.C.-based PPD has a compound-partnering program… more...
On Sept. 30, 2004, the day Merck withdrew Vioxx from the market, Lancashire, England’s Synexus Clinical Research was working on the biggest Vioxx trial ever. “I nearly jumped out my office window,” jokes CEO Michael Fort. The Vioxx saga turned out to be a blessing for the company, however. The… more...
Oncology? Limiting? Not in the least. That’s what Tom Ludlam says. He’s CEO of the Columbus, Ohio-based contract research organization (CRO) Prologue, which only conducts cancer trials. The company has more work than it can shake a stick at. “There is certainly plenty of opportunity,” Ludlam says. That’s putting it… more...